Iron chelators as mitophagy agents: Potential and limitations
Language English Country France Media print-electronic
Document type Journal Article, Review
PubMed
39265234
DOI
10.1016/j.biopha.2024.117407
PII: S0753-3322(24)01292-7
Knihovny.cz E-resources
- Keywords
- Cancer, Cardiovascular diseases, Iron chelators, Iron heomeostais, Mitophagy, Neurodegenerative diseases,
- MeSH
- Iron Chelating Agents * pharmacology therapeutic use MeSH
- Homeostasis drug effects MeSH
- Humans MeSH
- Mitochondria * metabolism drug effects MeSH
- Mitophagy * drug effects MeSH
- Iron * metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Iron Chelating Agents * MeSH
- Iron * MeSH
Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
References provided by Crossref.org
